News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DBV Technologies Demonstrates Ability of VIASKIN® to Administer Allergen via Intact Skin by Targeting Dendritic Cells for Safe Treatment of Allergic Disease



5/17/2011 10:40:21 AM

PARIS--(BUSINESS WIRE)--DBV Technologies, an emerging biotechnology company, announced today that a study1—“Epicutaneous Immunotherapy (EPIT) Results in Rapid Allergen Uptake by Dendritic Cells through Intact Skin and Downregulates the Allergen-Specific Response in Mice“—published in the Journal of Immunology confirms the safety of the Company’s VIASKIN® epicutaneous immunotherapy (EPIT) approach to desensitizing against peanut allergy via a novel and patented skin patch.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES